These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

87 related items for PubMed ID: 9031453

  • 1. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia.
    de Maat MP, Knipscheer HC, Kastelein JJ, Kluft C.
    Thromb Haemost; 1997 Jan; 77(1):75-9. PubMed ID: 9031453
    [Abstract] [Full Text] [Related]

  • 2. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients.
    Kockx M, de Maat MP, Knipscheer HC, Kastelein JJ, Kluft C, Princen HM, Kooistra T.
    Thromb Haemost; 1997 Oct; 78(4):1167-72. PubMed ID: 9364979
    [Abstract] [Full Text] [Related]

  • 3. Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia.
    Knipscheer HC, de Valois JC, van den Ende B, Wouter ten Cate J, Kastelein JJ.
    Atherosclerosis; 1996 Jul; 124 Suppl():S75-81. PubMed ID: 8831919
    [Abstract] [Full Text] [Related]

  • 4. Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII.
    Bröijersén A, Hamsten A, Silveira A, Fatah K, Goodall AH, Eriksson M, Angelin B, Hjemdahl P.
    Thromb Haemost; 1996 Aug; 76(2):171-6. PubMed ID: 8865525
    [Abstract] [Full Text] [Related]

  • 5. Homocysteine elevation with fibrates: is it a class effect?
    Harats D, Yodfat O, Doolman R, Gavendo S, Marko D, Shaish A, Sela BA.
    Isr Med Assoc J; 2001 Apr; 3(4):243-6. PubMed ID: 11344833
    [Abstract] [Full Text] [Related]

  • 6. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Aguilar-Salinas CA, Fanghänel-Salmón G, Meza E, Montes J, Gulías-Herrero A, Sánchez L, Monterrubio-Flores EA, González-Valdez H, Gómez Pérez FJ.
    Metabolism; 2001 Jun; 50(6):729-33. PubMed ID: 11398153
    [Abstract] [Full Text] [Related]

  • 7. Modulation of plasma fibrinogen levels by ticlopidine in healthy volunteers and patients with stable angina pectoris.
    de Maat MP, Arnold AE, van Buuren S, Wilson JH, Kluft C.
    Thromb Haemost; 1996 Aug; 76(2):166-70. PubMed ID: 8865524
    [Abstract] [Full Text] [Related]

  • 8. Effect of ciprofibrate on C-reactive protein and fibrinogen levels.
    Rizos E, Kostoula A, Elisaf M, Mikhailidis DP.
    Angiology; 2002 Aug; 53(3):273-7. PubMed ID: 12025914
    [Abstract] [Full Text] [Related]

  • 9. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice.
    Mikhailidis DP, Ganotakis ES, Spyropoulos KA, Jagroop IA, Byrne DJ, Winder AF.
    Int Angiol; 1998 Dec; 17(4):225-33. PubMed ID: 10204653
    [Abstract] [Full Text] [Related]

  • 10. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes.
    Rizos E, Bairaktari E, Ganotakis E, Tsimihodimos V, Mikhailidis DP, Elisaf M.
    J Cardiovasc Pharmacol Ther; 2002 Oct; 7(4):219-26. PubMed ID: 12490967
    [Abstract] [Full Text] [Related]

  • 11. [Changes in serum lipids, plasma fibrinogen and other haemostatic parameters induced by ciprofibrate action in hyperlipidemic patients with and without coronary artery disease].
    Espinosa RA, Rodríguez-Roa E, Nagy E, Mijares ME, Rodríguez-Larralde A, Gil A, Lundberg U, Carvajal Z, Castillo L, Arocha-Piñango CL.
    Invest Clin; 2006 Mar; 47(1):35-48. PubMed ID: 16562643
    [Abstract] [Full Text] [Related]

  • 12. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A, Comlekci A, Temiz A, Caliskan S, Ceylan C, Alacacioglu A, Yesil S.
    Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
    [Abstract] [Full Text] [Related]

  • 13. [Effect of ciprofibrate on the endothelial dysfunction of patients with combined dyslipidemia].
    Kovács I, Tarján J, Császár A.
    Orv Hetil; 2001 Apr 15; 142(15):775-9. PubMed ID: 11367862
    [Abstract] [Full Text] [Related]

  • 14. Effect of ciprofibrate on fibrinogen synthesis in vitro on hepatoma cells and in vivo in genetically obese Zucker rats.
    Herbert JM, Bernat A, Chatenet-Duchène L.
    Blood Coagul Fibrinolysis; 1999 Jul 15; 10(5):239-44. PubMed ID: 10456614
    [Abstract] [Full Text] [Related]

  • 15. Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome.
    Jastrzebska M, Torbus-Lisiecka B, Pieczul-Mróz J, Chelstowski K, Kopciewicz J, Naruszewicz M.
    Int J Clin Pharmacol Res; 1999 Jul 15; 19(1):19-25. PubMed ID: 10450539
    [Abstract] [Full Text] [Related]

  • 16. Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?
    Balogh Z, Seres I, Harangi M, Kovács P, Kakuk G, Paragh G.
    Diabetes Metab; 2001 Nov 15; 27(5 Pt 1):604-10. PubMed ID: 11694861
    [Abstract] [Full Text] [Related]

  • 17. [Long-term hypolipidemic treatment of mixed hyperlipidemia with a combination of statins and fibrates].
    Zeman M, Zák A, Vecka M, Romaniv S.
    Cas Lek Cesk; 2003 Aug 15; 142(8):500-4. PubMed ID: 14626567
    [Abstract] [Full Text] [Related]

  • 18. Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia.
    Vigna GB, Donega P, Passaro A, Zanca R, Cattin L, Fonda M, Pauciullo P, Marotta G, Fellin R, Gasparrini S, Piliego T.
    Nutr Metab Cardiovasc Dis; 1999 Oct 15; 9(5):234-43. PubMed ID: 10656170
    [Abstract] [Full Text] [Related]

  • 19. The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels.
    Dierkes J, Westphal S, Luley C.
    Expert Opin Drug Saf; 2004 Mar 15; 3(2):101-11. PubMed ID: 15006716
    [Abstract] [Full Text] [Related]

  • 20. Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men.
    Hernández C, Lecube A, Barberá G, Chacón P, Lima J, Simó R.
    Med Sci Monit; 2003 Mar 15; 9(3):CR114-9. PubMed ID: 12640339
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.